629 related articles for article (PubMed ID: 29083450)
1. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
Hahn B
Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
[TBL] [Abstract][Full Text] [Related]
2. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
3. The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder.
Garel N; Greenway K; Joober R
J Psychiatry Neurosci; 2021 Jan; 46(1):E164-E165. PubMed ID: 33464779
[No Abstract] [Full Text] [Related]
4. Effect of prior foot shock stress and Δ
Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA
Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
6. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Deiana S
Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
[TBL] [Abstract][Full Text] [Related]
7. Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series.
Schipper R; Dekker M; de Haan L; van den Brink W
J Psychopharmacol; 2018 Mar; 32(3):353-356. PubMed ID: 29039260
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis.
Mielnik CA; Li CK; Ramsey AJ; Salahpour A; Burnham WM; Ross RA
Cannabis Cannabinoid Res; 2024 Feb; 9(1):174-187. PubMed ID: 36251462
[No Abstract] [Full Text] [Related]
9. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.
Campos AC; Moreira FA; Gomes FV; Del Bel EA; Guimarães FS
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3364-78. PubMed ID: 23108553
[TBL] [Abstract][Full Text] [Related]
10. Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.
Breuer A; Haj CG; Fogaça MV; Gomes FV; Silva NR; Pedrazzi JF; Del Bel EA; Hallak JC; Crippa JA; Zuardi AW; Mechoulam R; Guimarães FS
PLoS One; 2016; 11(7):e0158779. PubMed ID: 27416026
[TBL] [Abstract][Full Text] [Related]
11. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
Arnold JC; Boucher AA; Karl T
Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol as a potential treatment for psychosis.
Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
[TBL] [Abstract][Full Text] [Related]
14. The relationship between cannabidiol and psychosis: A review.
Silva TB; Balbino CQ; Weiber AF
Ann Clin Psychiatry; 2015 May; 27(2):134-41. PubMed ID: 25954940
[TBL] [Abstract][Full Text] [Related]
15. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties.
Sharpe L; Sinclair J; Kramer A; de Manincor M; Sarris J
J Transl Med; 2020 Oct; 18(1):374. PubMed ID: 33008420
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
[TBL] [Abstract][Full Text] [Related]
17. Female but not male rats show biphasic effects of low doses of Δ
Salviato BZ; Raymundi AM; Rodrigues da Silva T; Salemme BW; Batista Sohn JM; Araújo FS; Guimarães FS; Bertoglio LJ; Stern CA
Neuropharmacology; 2021 Sep; 196():108684. PubMed ID: 34181978
[TBL] [Abstract][Full Text] [Related]
18. Perspectives toward cannabidiol (CBD) among youth in Early Psychosis Intervention programs: A qualitative study.
Ghelani A
Early Interv Psychiatry; 2024 Jan; 18(1):10-17. PubMed ID: 37038248
[TBL] [Abstract][Full Text] [Related]
19. Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
Schubart CD; Sommer IE; van Gastel WA; Goetgebuer RL; Kahn RS; Boks MP
Schizophr Res; 2011 Aug; 130(1-3):216-21. PubMed ID: 21592732
[TBL] [Abstract][Full Text] [Related]
20. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]